Dupilumab improves long-term outcomes in patients with uncontrolled, moderate-to-severe GINA-based type 2 asthma, irrespective of allergic status.
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
revised:
06
04
2023
received:
28
09
2022
accepted:
07
04
2023
medline:
1
8
2023
pubmed:
19
4
2023
entrez:
19
04
2023
Statut:
ppublish
Résumé
Previous research has shown greater efficacy of dupilumab in patients with uncontrolled asthma and type 2 inflammation. We analyzed dupilumab's efficacy in patients from the TRAVERSE study with or without evidence of allergic asthma and type 2 inflammation per current GINA guidelines (≥150 eosinophils/μL or FeNO ≥20 ppb). All patients aged ≥12 years who rolled over from the placebo-controlled QUEST study (NCT02414854) to TRAVERSE (NCT02134028) received add-on dupilumab 300 mg every 2 weeks for up to 96 weeks. We assessed annualized severe asthma exacerbation rates (AERs) and changes from parent-study baseline (PSBL) in pre-bronchodilator FEV In TRAVERSE, dupilumab consistently reduced AER across all subgroups. By Week 96, dupilumab increased pre-bronchodilator FEV Long-term treatment with dupilumab reduced exacerbation rates and improved lung function and asthma control in patients with asthma with type 2 inflammation as per current GINA guidance and irrespective of evidence of allergic asthma.
Sections du résumé
BACKGROUND
Previous research has shown greater efficacy of dupilumab in patients with uncontrolled asthma and type 2 inflammation. We analyzed dupilumab's efficacy in patients from the TRAVERSE study with or without evidence of allergic asthma and type 2 inflammation per current GINA guidelines (≥150 eosinophils/μL or FeNO ≥20 ppb).
METHODS
All patients aged ≥12 years who rolled over from the placebo-controlled QUEST study (NCT02414854) to TRAVERSE (NCT02134028) received add-on dupilumab 300 mg every 2 weeks for up to 96 weeks. We assessed annualized severe asthma exacerbation rates (AERs) and changes from parent-study baseline (PSBL) in pre-bronchodilator FEV
RESULTS
In TRAVERSE, dupilumab consistently reduced AER across all subgroups. By Week 96, dupilumab increased pre-bronchodilator FEV
CONCLUSIONS
Long-term treatment with dupilumab reduced exacerbation rates and improved lung function and asthma control in patients with asthma with type 2 inflammation as per current GINA guidance and irrespective of evidence of allergic asthma.
Substances chimiques
dupilumab
420K487FSG
Bronchodilator Agents
0
Antibodies, Monoclonal
0
Anti-Asthmatic Agents
0
Banques de données
ClinicalTrials.gov
['NCT02414854', 'NCT02134028']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2148-2156Informations de copyright
© 2023 Sanofi and The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Updated 2021. Accessed January 10, 2022. https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf
Fahy JV. Type 2 inflammation in asthma-present in most, absent in many. Nat Rev Immunol. 2015;15(1):57-65.
Le Floc'h A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188-1204.
Macdonald LE, Karow M, Stevens S, et al. Precise and in situ genetic humanization of 6 mb of mouse immunoglobulin genes. Proc Natl Acad Sci USA. 2014;111(14):5147-5152.
Murphy AJ, Macdonald LE, Stevens S, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci U S A. 2014;111(14):5153-5158.
Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425-437.
Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. NEJM. 2018;378(26):2486-2496.
Wechsler ME, Ford LB, Maspero JF, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2022;10(1):11-25.
Menzies-Gow A, Flood-Page P, Sehmi R, et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol. 2003 Apr;111(4):714-719.
Walsh GM. Mepolizumab and eosinophil-mediated disease. Curr Med Chem. 2009;16(36):4774-4778.
Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011 May 3;154(9):573-582. Erratum in: Ann Intern Med. 2019 Oct 1;171(7):528.
Sposato B, Ricci A, Camiciottoli G, et al. Influence of allergic status and nasal polyposis on long-term benralizumab response in eosinophilic severe asthma. Clin Ter. 2023;174(1):67-74.
Salvati L, Liotta F, Annunziato F, et al. Therapeutical targets in allergic inflammation. Biomedicines. 2022;10(11):2874.
Corren J, Castro M, O'Riordan T, et al. Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma. J Allergy Clin Immunol Pract. 2020;8(2):516-526.
Rabe KF, FitzGerald JM, Bateman ED, et al. Dupilumab is effective in patients with moderate-to-severe uncontrolled GINA-defined type 2 asthma irrespective of an allergic asthma phenotype. J Allergy Clin Immunol Pract. 2022;10(11):2916-2924.
Brusselle G, Quirce S, Papi A, et al. Dupilumab efficacy in patients with uncontrolled or oral corticosteroid-dependent allergic and nonallergic asthma. J Allergy Clin Immunol Pract. 2022;11(3):873-884.
Akenroye AT, Segal JB, Zhou G, et al. Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: a target trial. J Allergy Clin Immunol. 2023. doi:10.1016/j.jaci.2023.01.020
Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Updated 2014. Accessed January 10, 2022. https://ginasthma.org/wp-content/uploads/2019/01/2014-GINA.pdf
Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31-44.
Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. NEJM. 2018;378(26):2475-2485.
Juniper EF, Svensson K, Mörk AC, Ståhl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med. 2005;99(5):553-558.